Rasagiline ameliorates olfactory deficits in an alpha-synuclein mouse model of Parkinson's disease. - Wikidata - awgldk - TriplyDB

Rasagiline ameliorates olfactory deficits in an alpha-synuclein mouse model of Parkinson's disease.

Rasagiline ameliorates olfactory deficits in an alpha-synuclein mouse model of Parkinson's disease.

http://www.wikidata.org/entity/Q34662060

about

What can rodent models tell us about apathy and associated neuropsychiatric symptoms in Parkinson's disease?Systemically administered anti-TNF therapy ameliorates functional outcomes after focal cerebral ischemia.Holocranohistochemistry enables the visualization of α-synuclein expression in the murine olfactory system and discovery of its systemic anti-microbial effects History of smoking and olfaction in Parkinson's disease.Olfactory dysfunction and neurotransmitter disturbance in olfactory bulb of transgenic mice expressing human A53T mutant α-synuclein.Mannose 6-Phosphate Receptor Is Reduced in -Synuclein Overexpressing Models of Parkinsons Disease.Olfactory bulb involvement in neurodegenerative diseases.Development of Passive Immunotherapies for Synucleinopathies.Non-motor features of Parkinson disease.Animal models of α-synucleinopathy for Parkinson disease drug development.Early Parkinson's disease patients on rasagiline present with better odor discrimination.5-HT2A Receptor Binding in the Frontal Cortex of Parkinson's Disease Patients and Alpha-Synuclein Overexpressing Mice: A Postmortem Study.Effects of rasagiline on olfactory function in patients with Parkinson’s disease.

P2860

Q26767268-DCAC5FAB-4998-438E-A537-4132AC44A98E Q30610169-E65BD38E-0A37-4C5C-A93C-BB5B0734BF94 Q33734084-A4FA5A16-FA84-4056-907F-1445583D05F5 Q33934900-70447422-8A95-4CB7-95CD-A7EC3A83260C Q35208334-8584EC6B-520D-46DD-BFD4-E2E80F92C8B5 Q36100354-AB4C14AB-DDF3-4068-8A26-2AF80A4494B0 Q38189727-7320C1F0-4D8C-4D30-97D0-063E9636D582 Q38679627-06FA1217-B886-4ED6-803E-F414AE3F7F36 Q39358549-AFE927CD-17B0-4373-8362-8CAF802E00D2 Q40106906-CF5C18CA-C0DC-47B9-8FD9-ADE62299E2AB Q40680514-EF4CD3C4-AD1D-47DB-A4FE-D499AFF0C1A7 Q41694670-06D4472F-CAFA-43E1-9D28-5770A2145E8E Q48140409-6223A8DE-EA93-4C0C-9E64-05BD32E008F1

P2860

Rasagiline ameliorates olfactory deficits in an alpha-synuclein mouse model of Parkinson's disease.

http://www.wikidata.org/entity/Q34662060

description

2013 nî lūn-bûn

@nan

2013 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Rasagiline ameliorates olfacto ...... model of Parkinson's disease.

@ast

Rasagiline ameliorates olfacto ...... model of Parkinson's disease.

@en

Rasagiline ameliorates olfacto ...... model of Parkinson's disease.

@nl

type

label

Rasagiline ameliorates olfacto ...... model of Parkinson's disease.

@ast

Rasagiline ameliorates olfacto ...... model of Parkinson's disease.

@en

Rasagiline ameliorates olfacto ...... model of Parkinson's disease.

@nl

prefLabel

Rasagiline ameliorates olfacto ...... model of Parkinson's disease.

@ast

Rasagiline ameliorates olfacto ...... model of Parkinson's disease.

@en

Rasagiline ameliorates olfacto ...... model of Parkinson's disease.

@nl

P1433

Q34662060-3F0F3086-72C5-4B12-9DC7-4D7DA2E1945C

P1476

Q34662060-87329775-3437-416C-A71E-6D0671A1BDA2

P2093

Q34662060-11C0D6A6-B04F-45C7-BDF0-F175F791B83C

Q34662060-41D7F78A-A716-490C-AAC6-3D42563B5243

Q34662060-43D8F39C-773E-4444-8DA7-ED264C2A4AFD

Q34662060-460BD22F-6966-466B-B239-91CA6F3B772F

Q34662060-5C011F2F-B9F5-44A8-9994-5C51015F183F

Q34662060-D1F89468-0E3F-42CB-B083-1E138303E527

P2860

Q34662060-08ACF962-2214-4E0C-968A-3887F8B0EE77

Q34662060-09244F82-F505-4689-A7AF-0FD221FD650C

Q34662060-09F828F8-ED5A-4E17-A947-EF4997C9DC1B

Q34662060-0D40378D-D123-449D-8232-F6739E61C8A7

Q34662060-11353A84-5DE1-46C7-9983-277432B1B353

Q34662060-15AD3FEB-3560-4430-AB96-45FD21C88051

Q34662060-17A6CD88-991A-482C-8758-96930836B590

Q34662060-1912006A-32C7-4717-9DDD-646757918D82

Q34662060-1BB065E1-D2A9-4737-B99B-71B3E008CD39

Q34662060-1C4D6FF6-0498-4674-83DA-615A29685F9C

P304

Q34662060-70DACF98-2178-4BAF-99C3-547706573BE3

P31

Q34662060-5B34CDC0-D956-4D30-9476-530052E7E3C0

P356

Q34662060-3C10C3D0-F160-4CA8-8CAE-767E4F8E63AC

P407

Q34662060-95A80CD9-AD96-4C3C-89F2-BD5A9688767D

P433

Q34662060-9B9030B3-E4FB-479D-8E84-9DDA4BE2968D

P478

Q34662060-3C126996-1F9C-4AD8-8A17-20AC654D17CC

P50

Q34662060-16FB18C0-6ED7-4BE6-A078-921F39A6A034

P577

Q34662060-8D8437B4-9E07-4996-8C3B-5424D35A8BF9

P5875

Q34662060-B0BB3850-B8DD-4314-8AF3-0558DD61B850

P698

Q34662060-C9D50671-7D1B-42EC-9E14-1930957EC39E

P921

Q34662060-A3AA85B7-E833-4758-8771-5D4463268C62

Q34662060-ADFE33C4-DA1C-4B0A-BDD0-D2EA44EA6007

P932

Q34662060-774F9A7D-061B-4330-B8FB-6204A4EAD054

P356

JOURNAL.PONE.0060691

P1433

P1476

Rasagiline ameliorates olfacto ...... model of Parkinson's disease.

@en

P2093

Cheryl Fitzer-Attas

http://www.w3.org/2001/XMLSchema#string

Elijahu Berkovich

http://www.w3.org/2001/XMLSchema#string

Géraldine H Petit

http://www.w3.org/2001/XMLSchema#string

Karina Fog

http://www.w3.org/2001/XMLSchema#string

Mark Hickery

http://www.w3.org/2001/XMLSchema#string

Pekka Kallunki

http://www.w3.org/2001/XMLSchema#string

P2860

Sniffing out the contributions of the olfactory tubercle to the sense of smell: hedonics, sensory integration, and more?

Olfactory discrimination deficits in mice lacking the dopamine transporter or the D2 dopamine receptor

Molecular cloning of canine monoamine oxidase subtypes A (MAOA) and B (MAOB) cDNAs and their expression in the brain.

Mutant alpha-synuclein exacerbates age-related decrease of neurogenesis.

Dopamine depletion impairs precursor cell proliferation in Parkinson disease.

A randomized placebo-controlled trial of rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations: the PRESTO study.

A double-blind, delayed-start trial of rasagiline in Parkinson's disease.

Olfactory deficits in mice overexpressing human wildtype alpha-synuclein.

The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline.

Rasagiline: neurodegeneration, neuroprotection, and mitochondrial permeability transition.

P304

e60691

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0060691

http://www.w3.org/2001/XMLSchema#string

P407

P433

4

http://www.w3.org/2001/XMLSchema#string

P478

8

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-04-03T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236189892

http://www.w3.org/2001/XMLSchema#string

P698

23573275

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

P932

3616111

http://www.w3.org/2001/XMLSchema#string